Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effecti...
The following slide deck was published by Glaukos Corporation in conjunction with this event. For further details see: Glaukos (GKOS) Investor presentation - slideshow
Image source: The Motley Fool. Glaukos Corp (NYSE: GKOS) FY 2021 Earnings Call Nov 29, 2021 , 3:00 p.m. ET Chris Cooley -- Analyst Continue reading For further details see: Glaukos Corp (GKOS) FY 2021 Earnings Call Transcript
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be highlighted in various scientific programming at...
Glaukos Corporation (GKOS) Q3 2021 Earnings Conference Call November 04, 2021 04:30 PM ET Company Participants Chris Lewis - Senior Director, Investor Relations and Corporate Strategy and Development Tom Burns - President and CEO Joe Gilliam - Chief Financial Officer Chris Calcaterra - Chief ...
Glaukos (NYSE:GKOS): Q3 Non-GAAP EPS of -$0.21 beats by $0.03; GAAP EPS of $0.13 beats by $0.45. Revenue of $74.7M (+15.3% Y/Y) beats by $1.97M. Press Release Gross margin of approximately 79% and non-GAAP gross margin of approximately 87% in Q3 2021. For further details see: Glaukos EP...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2021. Key highlight...
Shares of Glaukos (NYSE: GKOS) were soaring 18.5% as of 11:58 a.m. EDT on Wednesday. The big jump came after the Centers for Medicare & Medicaid Services (CMS) published its final payment rates for 2022. Glaukos revealed the CMS update in a filing with the U.S. Securities an...
Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +110%, iRhythm Technologies IRTC +44%, Karyopharm Therapeutics KPTI +31%, Glaukos GKOS +25%, Rafael RFL +15%. Losers: Cardiol Therapeutics CRDL -25%, Bone Biologics (OTCPK:BBLG) -15%, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re starting the day off right with a dive into the biggest pre-market stock movers for Wednesday! Source: ventdusud / Shutterstock.com We’ve got plenty of news to talk about th...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...